Advanced practice providers (APPs) can play a major role for patients being treated for multiple myeloma. In this video interview, Donna Catamero, ANP-BC, OCN, CCRC, shares the basics you should know! 👉hubs.ly/Q04BMghl0 #MultipleMyeloma #OncologyAPP

Sequential #cytarabine induction followed by #azacitidine plus #lenalidomide showed clinical activity in very-high-risk #MDS, suggesting a potential treatment approach in resource-limited settings. Learn more: hmpgloballearningnetwork.com…

Want to catch up on the latest research presented at this year's JADPRO Live conference? Check in with the JADPRO Live newsroom, here: hubs.ly/Q04BMb9M0 #JADPROLive2026 #OncologyAPP

Catherine Diefenbach, MD, discusses evolving frontline treatment options for classical #Hodgkin lymphoma, highlighting the importance of balancing efficacy, toxicity, and financial burden as #immunotherapy-based regimens expand. Learn more: hmpgloballearningnetwork.com…

In this APP Institute case presentation, Mary Steinbach, NP, discusses extramedullary progression after CAR-T therapy in a patient with high-risk multiple myeloma. Learn more: hubs.ly/Q04BDQM40 #multiplemyeloma #howitreat

🚨: @FDA grants accelerated approval to #dostarlimab (Jemperli) for stage II/III MSI-H/dMMR locally advanced rectal cancer based on #AZUR1 results, offering a potential organ-preserving treatment approach. Learn more: hmpgloballearningnetwork.com…

In this video interview, Madeline Merrill, AGNP-BC, MSN, discusses care delivery innovations highlighted at the 2026 ASCO Annual Meeting and their implications for oncology APPs. Learn more: hubs.ly/Q04Bls0q0 #ASCO2026 #cancercaredelivery

In this video interview, Sally Fang, MSN, RN, FNP-BC, tackles the question of what it means to be an APP in the evolving field of breast medical oncology. Watch now on the APP Institute! 🔗hubs.ly/Q04BbPhX0 #BreastCancer #OncologyAPP

🚨: The @FDA has expanded approval of nogapendekin alfa inbakicept plus BCG to include patients with BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only tumors. Learn more: hmpgloballearningnetwork.com…

Marlise Luskin, MD, discusses the evolving role of #MRD assessment in #ALL, highlighting its potential to guide treatment decisions, refine risk stratification, and reduce unnecessary chemotherapy exposure. Learn more: hmpgloballearningnetwork.com…

The conversation continues off the stage 🎥 We sat down with @SoniSmithMD and @NGhoshMD to dig deeper into their perspectives and the clinical implications of today’s discussions. Stay tuned! #LLMcongress #medtwitter #onctwitter

In part 2 of their video interview, Dr. Tanios Bekaii-Saab and Jonathan Catrona discuss some of the top highlights in GI cancer out of this year's ASCO Annual Meeting. Watch Now: hubs.ly/Q04B3tbw0 #ASCO2026 #GICancer

Watch Now: @AjayNookaMD breaks down #MonumenTAL6 findings and the potential of #talquetamab-based combinations to improve outcomes in relapsed or refractory multiple #myeloma. Learn more: hmpgloballearningnetwork.com… #medtwitter #onctwitter

Join Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP, as they discuss key lung cancer findings from the 2026 ASCO Annual Meeting and their implications for oncology APPs. Watch now: hubs.ly/Q04ztN580 #lungcancer #ASCO2026annualmeeting

🚨 The @FDA has approved #atezolizumab plus chemo for patients aged 2 years and older, bringing PD-L1 inhibition into the postoperative setting following positive #ATOMIC trial results. Learn more: hmpgloballearningnetwork.com…

AI is one of the hottest topics in oncology. Join Jasmin Hundal, MD, DipABLM, MS, MPH, to learn about the latest updates in AI as presented at the 2026 ASCO annual meeting and how these advances apply to practice for APPs. 🔗 hubs.ly/Q04ztN510 #OncologyAPP #OncologyAI

🚨 The @FDA has approved #tucatinib plus #trastuzumab and #pertuzumab as maintenance therapy following first-line induction for advanced #HER2-positive #breastcancer, bringing a new HER2-targeted strategy into the maintenance setting. Learn more: hmpgloballearningnetwork.com…

Which innovation in pancreatic cancer received a standing ovation at the ASCO 2026 Annual Meeting? Find out in this video featuring Tanios Bekaii-Saab, MD, and Jonathan Catrona, PA-C. Watch here: hubs.ly/Q04zmH370 #ASCO2026 #PancreaticCancer #GICancer

Results from the #TOSCA trial demonstrated that #cemiplimab significantly improved survival compared with historical control in locally advanced or metastatic #cSCC when curative surgery or radiotherapy was not an option. Learn more: hmpgloballearningnetwork.com…